



## MATERIAL SAFETY DATA SHEET

### SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY

<b>Pfizer Inc</b>	<b>Emergency telephone</b>	1-866-531-8896
<b>Pfizer Animal Health</b>	<b>Hours of operation</b>	24 Hours
<b>235 East 42nd Street</b>	<b>Telephone</b>	1-800-366-5288
<b>New York, NY 10017</b>		

<b>Trade names</b>	<b>ALBON® TABLETS</b>
<b>Product name</b>	<b>ALBON® (sulfadimethoxine) TABLETS</b>
<b>Synonyms</b>	<b>Sulfadimethoxine Tablets</b>
<b>Chemical family</b>	Sulfonamide
<b>Therapeutic use</b>	Antibiotic agent
<b>Description</b>	White to off-white cylindrical tablet

### SECTION 2 - COMPOSITION

<u>Ingredient</u>	<u>CAS Number</u>	<u>Amount</u>
Sulfadimethoxine*	122-11-2	83.5%
Alginic acid*	9005-32-7	Proprietary
Gelatin	9000-70-8	Proprietary
Magnesium stearate*	557-04-0	Proprietary
Starch, pregelatinized NF*	9005-25-8	Proprietary
Talc (nonasbestiform)*	14807-96-6	Proprietary

\*Hazardous

Note: Ingredient(s) indicated as hazardous have been assessed under US OSHA Hazard Communication Standard for workplace safety (29 CFR 1910.1200).

### SECTION 3 - HAZARDS IDENTIFICATION

<b>Signal word</b>	<b>CAUTION!</b>
<b>Statements of hazard</b>	<b>MAY CAUSE ALLERGIC REACTION IN INDIVIDUALS SENSITIVE TO SULFONAMIDES.</b>
<b>Eye effects</b>	Not expected due to physical form.
<b>Skin effects</b>	Contact with sulfonamides may cause dermatitis. Allergic skin reaction may occur based on effects of other sulfonamides.
<b>Inhalation effects</b>	An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8). See 'Statements of hazard' and/or 'Other potential health effects' in this section.

---

### SECTION 3 - HAZARDS IDENTIFICATION ... continued

---

<b>Ingestion effects</b>	Accidental ingestion may cause effects similar to those seen in clinical use. See 'Statements of hazard' and/or 'Other potential health effects' in this section.
<b>Other potential health effects</b>	Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. As in all sulfonamide therapy, the following reactions may occur including nausea, vomiting, diarrhea, inflammation of the liver and pancreas, blood disorder, drug fever, skin rash, infection of the conjunctiva and sclera, blood in the urine and crystalluria.
<b>NOTE:</b>	This document has been prepared in accordance with the US OSHA Hazard Communication Standard, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace. If your workplace is regulated by OSHA, this document must be used as a part of a complete hazard-training program.

---

### SECTION 4 - FIRST AID MEASURES

---

<b>Skin</b>	Remove contaminated clothing and shoes. Wash skin with soap and water. Wash clothing and thoroughly clean shoes before reuse. If irritation occurs or persists, get medical attention.
<b>Eyes</b>	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
<b>Inhalation</b>	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.
<b>Ingestion</b>	Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

---

### SECTION 5 - FIRE FIGHTING MEASURES

---

<b>Fire fighting instructions</b>	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.
<b>Extinguishing media</b>	Water, dry powder or foam extinguishers are recommended.
<b>Flash point</b>	Not applicable
<b>Hazardous combustion products</b>	Not known

---

## SECTION 6 - ACCIDENTAL RELEASE MEASURES

---

<b>General</b>	Review Sections 3, 8 and 12 before proceeding with clean up.
<b>Small spill</b>	Vacuum or sweep material into appropriate recovery container. Clean spill area thoroughly.
<b>Large spill</b>	Vacuum or sweep material into appropriate recovery container. Close container and move it to a secure holding area.

---

## SECTION 7 - HANDLING AND STORAGE

---

<b>General handling</b>	IF TABLETS OR CAPSULES ARE CRUSHED AND/OR BROKEN, AVOID INHALING DUST OR CONTACT WITH EYES, SKIN AND CLOTHING. Use only in a well-ventilated area.
<b>Storage conditions</b>	Store in a cool, dry place.
<b>Temperature range for storage</b>	Store as directed by product packaging.

---

## SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

---

<b>Exposure limits</b>			
<u>Compound</u>	<u>Issuer</u>	<u>Type</u>	<u>OEL</u>
Starch, pregelatinized NF	OSHA	TWA-8 Hr	5 mg/m <sup>3</sup> (respirable fraction)
	OSHA	TWA-8 Hr	15 mg/m <sup>3</sup> (total dust)
	ACGIH	TWA-8 Hr	10 mg/m <sup>3</sup> (total dust)
<b>Exposure information</b>	The exposure limit(s) listed for solid components are only relevant if dust may be generated.		
<b>Ventilation</b>	General room ventilation is adequate unless the process generates dust, mist or fumes.		
<b>Respiratory protection</b>	Respiratory protection is not expected to be necessary under normal handling conditions; required only if dust is generated.		
<b>Eye protection</b>	Not required under normal conditions of use.		
<b>Skin protection</b>	Wear protective clothing when working with large quantities.		
<b>Hand protection</b>	Wear gloves when working with large quantities.		

---

## SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

---

<b>Physical form</b>	Cylindrical tablet
<b>Color</b>	White to off-white
<b>Molecular weight</b>	Mixture

---

**SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES** ... continued

---

<b>Molecular formula</b>	Mixture
<b>pH</b>	Not applicable
<b>Boiling point</b>	Not applicable
<b>Melting point</b>	No data available
<b>Density</b>	Not applicable
<b>Vapor pressure</b>	Not applicable
<b>Water solubility</b>	No data available
<b>Solvent solubility</b>	No data available

---

**SECTION 10 - STABILITY AND REACTIVITY**

---

<b>Reactivity</b>	Stable
<b>Conditions to avoid</b>	Direct sunlight, conditions that might generate heat and dispersion as a dust cloud
<b>Incompatibilities</b>	Strong oxidizers
<b>Hazardous decomposition products</b>	No data available
<b>Hazardous polymerization</b>	Will not occur

---

**SECTION 11 - TOXICOLOGY INFORMATION**

---

**Toxicology summary**      There are no data for this formulation. The information included in this section describes the potential hazards of the active ingredient, except where noted.

**Acute toxicity**

<u>Compound</u>	<u>Type</u>	<u>Route</u>	<u>Species</u>	<u>Dosage</u>
Sulfadimethoxine	LD <sub>50</sub>	Oral	Rat	>10 g/kg
Magnesium stearate	LD <sub>50</sub>	Oral	Rat	>1000 mg/kg
	LC <sub>50</sub>	Inhalation	Rat	>2000 mg/m <sup>3</sup>
Talc	LD <sub>50</sub>	Oral	Rat	>1600 mg/kg

**Eye**      Dust may cause irritation if tablets are crushed or broken

**Skin**      Dermatitis may occur from contact of sulfonamides with the skin.

**Inhalation**      See Acute toxicity table

**Ingestion**      See Acute toxicity table

---

**SECTION 11 - TOXICOLOGY INFORMATION** ... continued

---

<b>Mutagenicity</b>	Other sulfonamide drugs which have been evaluated are not mutagenic.
<b>Sensitization</b>	Hypersensitivity reactions to sulfonamides have been reported.
<b>Subchronic effects</b>	In rats, oral dosing of 9,100 mg/kg sulfadimethoxine for 13 weeks caused changes in thyroid weight (goitrogenic effect) and decreased weight gain. Sulfonamides are known to be goitrogenic, but not in primates or humans. Dogs given daily oral doses of 160 mg/kg sulfadimethoxine for 13 weeks showed no signs of toxicity.
<b>Chronic effects/ carcinogenicity</b>	Studies to evaluate the carcinogenic potential of sulfadimethoxine were not available. Other sulfonamide drugs which have been evaluated are not carcinogenic.
<b>Carcinogen status</b>	None of the components of this formulation is listed as a carcinogen by IARC, NTP or OSHA.
<b>Reproductive effects</b>	Not determined
<b>Teratogenicity</b>	In humans, sulfonamides administered prior to delivery can cause jaundice and hemolytic anemia in the offspring. Studies in pregnant laboratory animals administered sulfadimethoxine have shown developmental effects, but retrospective studies in humans with other sulfonamides have not been conclusive.
<b>At increased risk from exposure</b>	Like other sulfonamides, this material might produce hypersensitivity reactions in some individuals.

---

**SECTION 12 - ECOLOGICAL INFORMATION**

---

<b>Environmental overview</b>	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
-------------------------------	--

---

**SECTION 13 - DISPOSAL INFORMATION**

---

<b>Disposal procedure</b>	Incineration is the recommended method of disposal for this material. Observe all local and national regulations when disposing of this material.
---------------------------	---

---

**SECTION 14 - TRANSPORTATION INFORMATION**

---

<b>General shipping instructions</b>	Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
--	--

---

**SECTION 15 - REGULATORY INFORMATION**


---

<b>EU Classification</b>	Irritant
--------------------------	----------

---

**SECTION 15 - REGULATORY INFORMATION** ... continued

---

<b>EU Labelling</b>	<b>Xi</b>
<b>EU Label Pictogram(s)</b>	
<b>Risk phrases</b>	R43 - May cause sensitization by skin contact.
<b>Safety phrases</b>	S22 - Do not breathe dust. S37 - Wear suitable gloves.
<b>TSCA status</b>	Not listed
<b>SARA section 302</b>	No
<b>SARA section 313</b>	No
<b>California Proposition 65</b>	Not listed
<b>Canadian WHMIS</b>	Class D, Division 2, Subdivision B

---

**SECTION 16 - OTHER**

---

<b>Disclaimer</b>	<b>Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.</b>
-------------------	---